Federal Court rules against Biogen in trademark infringement dispute with Novartis
The Federal Court has prohibited Biogen from using a trademark for an ophthalmological drug, finding that its use of the mark would infringe Novartis’ right in a registered trademark for a...To view the full article, register now.
Already a subscriber? Click here to view full article